^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CJRB-101

    i
    Other names: CJRB-101
    Associations

    News

    Trials
    Company:
    CJ Biosci
    Drug class:
    Microbiome modulator
    Related drugs:
    Associations

    News

    Trials
    2ms
    Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma. (PubMed, J Immunother Cancer)
    Early clinical data show encouraging antitumor response of CJRB-101 plus pembrolizumab in ICI-naïve metastatic NSCLC with PD-L1 >50%.
    P1 data • Journal • PD(L)-1 Biomarker • IO biomarker • First-in-human
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • CJRB-101
    over2years
    Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer (clinicaltrials.gov)
    P1/2, N=160, Recruiting, CJ Bioscience, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    PD-L1 expression • BRAF mutation • BRAF V600
    |
    Keytruda (pembrolizumab) • CJRB-101
    3years
    Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer (clinicaltrials.gov)
    P1/2, N=160, Not yet recruiting, CJ Bioscience, Inc.
    New P1/2 trial • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    PD-L1 expression • BRAF mutation • BRAF V600
    |
    Keytruda (pembrolizumab) • CJRB-101